Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;23(3):547-565.
doi: 10.1007/s42000-024-00555-w. Epub 2024 Apr 6.

Association between serum TSH concentration and bone mineral density: an umbrella review

Martyna Dziedzic  1   2 , Michał Bonczar  3   4 , Patryk Ostrowski  3   4 , Bartłomiej Stachera  3   4 , Dawid Plutecki  4   5 , Monika Buziak-Bereza  6 , Alicja Hubalewska-Dydejczyk  6 , Jerzy Walocha  3   4 , Mateusz Koziej  3   4
Affiliations

Association between serum TSH concentration and bone mineral density: an umbrella review

Martyna Dziedzic et al. Hormones (Athens). 2024 Sep.

Abstract

Introduction: The aim of this study was to summarize the results of previous studies, standardize the data, and present new statistical results in order to provide physicians with clinically significant outcomes regarding the association between serum TSH concentration and bone mineral density (BMD).

Methods: To perform this umbrella review, a systematic search was conducted in which major online medical databases, such as PubMed, Web of Science, Embase, Scopus, Cochrane Library, and Google Scholar, were searched for meta-analyses and systematic reviews regarding the effect of TSH on BMD. Furthermore, all primary studies were screened for statistical analysis.

Results: The statistical outcomes of the present study were based on the data of 75,898 patients. The pooled risk ratio of any kind of fracture in patients with subclinical hyperthyroidism was estimated to be 1.36 (95% CI: 1.18-1.56; p < 0.001). The SMD for BMD in the distal radius in male patients receiving L-thyroxine suppression therapy was estimated to be -0.61 (95% CI: -1.10-(-0.11); p = 0.02). Furthermore, the pooled risk ratio of any fracture in patients receiving L-thyroxine suppression therapy was estimated to be 1.98 (95% CI: 0.98 - 3.98; p = 0.06). In these patients, the BMD may significantly differ from that in non-treated patients. However, the difference depends on the type of bone.

Conclusions: Our data confirmed that subclinical hyperthyroidism has a detrimental effect on bones, causing decreased BMD. Based on the obtained results, the authors suggest that a reduced TSH serum level itself may be an individual factor associated with decreased BMD and, thus, with a greater risk of bone fracture. Nevertheless, it should be noted that the effects of TSH suppression therapy differ between areas of interest for assessing BMD. Furthermore, the results have shown that this issue may, in specific areas, concern not only postmenopausal women but also male patients. These conclusions should contribute to a careful consideration of the application of TSH suppressive therapy in all patients. Particular attention should be given to patients after DTC, while all the advantages and disadvantages of implementing L-thyroxine therapy should be individually considered.

Keywords: BMD; Bone mineral density; Differentiated thyroid cancer; Subclinical hyperthyroidism; TSH; Thyroid-stimulating hormone.

PubMed Disclaimer

References

    1. Brancatella A, Marcocci C (2020) TSH suppressive therapy and bone. Endocr Connect 9:R158–R172. https://doi.org/10.1530/EC-20-0167 - DOI - PubMed - PMC
    1. Adlin EV, Maurer AH, Marks AD, Channick BJ (1991) Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 90:360–366. https://doi.org/10.1016/0002-9343(91)90577-K - DOI - PubMed
    1. Ma R, Morshed S, Latif R et al (2011) The Influence of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on Osteoclastogenesis. Thyroid 21:897–906. https://doi.org/10.1089/thy.2010.0457 - DOI - PubMed - PMC
    1. Yoon B-H, Lee Y, Oh HJ et al (2019) Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J Bone Metab 26:51. https://doi.org/10.11005/jbm.2019.26.1.51 - DOI - PubMed - PMC
    1. Wang M-Y, Han Z-Q, Gong X-W et al (2020) TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci 24:922–929. https://doi.org/10.26355/eurrev_202001_20077 - DOI - PubMed

Publication types

LinkOut - more resources